<PAGE> 1
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 28, 2000
DUSA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
NEW JERSEY 0-19777 22-3103129
(State or other (IRS Employer
jurisdiction of (Commission Identification
incorporation) File Number) Number)
25 UPTON DRIVE
WILMINGTON, MASSACHUSETTS 01887
(Address of principal executive offices, including ZIP code)
(978) 657-7500
(Registrant's telephone number, including area code)
<PAGE> 2
ITEM 5. OTHER EVENTS.
The Registrant, DUSA Pharmaceuticals, Inc., ("DUSA"), reports that it
has entered a Second Amendment to its Supply Agreement with Sochinaz, S.A., the
manufacturer of DUSA's drug product, aminolevulinic acid ("ALA"), as of June 20,
2000 (the "Second Amendment").
According to the terms of the transaction which closed on June 28,
2000, Sochinaz agreed to provide DUSA with an option to renew the Supply
Agreement for an additional three (3) years beyond its scheduled expiration date
on December 3, 2004. In addition, DUSA agreed to reimburse Sochinaz in the
amount of One Million Dollars (U.S. $1,000,000) for a portion of the costs
Sochinaz incurred to bring its manufacturing facility in Switzerland into
compliance with current Good Manufacturing Practices as established by the
United States Food and Drug Administration and for certain other development
costs related to ALA. Of this One Million Dollar (U.S. $1,000,000) amount,
$250,000 was paid in cash and $750,000 was paid by issuing Twenty-Six Thousand
Six Hundred Sixty Six (26,666) shares of DUSA's common stock, based upon the
closing price of DUSA's common stock as reported by the NASDAQ Stock Market on
June 20, 2000 (the "Shares").
The Shares, issued in a Regulation S private placement, do not carry
registration rights and are therefore subject to restrictions on transfer under
the Securities Act of 1933, as amended.
ITEM 7. FINANCIAL STATEMENTS AND OTHER EXHIBITS.
(c) Exhibits.
[10.1] Second Amendment to Supply Agreement, dated as of June 20, 2000.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DUSA PHARMACEUTICALS, INC.
Dated: June 29, 2000 By: /s/ D. Geoffrey Shulman
------------- -----------------------
D. Geoffrey Shulman, MD, FRCPC
President, Chief Executive Officer,
and Chief Financial Officer
